Skip to main content
. 2022 May 16;11(2):CNS87. doi: 10.2217/cns-2022-0005

Figure 1. . Clinical outcome data of WP1066 treated patients.

Figure 1. 

(A) PFS based on radiographic evidence of tumor progression based on the increase in the volume of gadolinium enhancement on magnetic resonance imaging and (B) OS from the time of tumor recurrence.

OS: Overall survival; PFS: Progression free survival.